Kazakhstan vs Senegal: Average cost of multi drug-resistant tuberculosis treatment
Kazakhstan
3,398 constant 2022 US$
in 2023
Senegal
3,428 constant 2022 US$
in 2024
Kazakhstan rank
13th
Senegal rank
12th
Average cost of multi drug-resistant tuberculosis treatment over time
- Kazakhstan
- Senegal
How they compare
Senegal currently reports 3,428 constant 2022 US$ against 3,398 constant 2022 US$ in Kazakhstan, a difference of 30 constant 2022 US$.
The two have swapped places 3 times across 5 shared years of data; in 2018 it was Kazakhstan ahead.
Kazakhstan ranks 13th and Senegal ranks 12th of 92 countries.
Across the 2 decades both report, Kazakhstan averaged higher in 1 and Senegal in 1.
Head to head by decade
| Decade | Kazakhstan | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,642 constant 2022 US$ | 2,555 constant 2022 US$ | 86.5 constant 2022 US$ | Kazakhstan |
| 2020s | 2,620 constant 2022 US$ | 2,741 constant 2022 US$ | 120.67 constant 2022 US$ | Senegal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Kazakhstan or Senegal?
- Senegal, at 3,428 constant 2022 US$ against 3,398 constant 2022 US$ in Kazakhstan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Kazakhstan and Senegal?
- 30 constant 2022 US$, with Senegal ahead.
- How many years of comparable data are there for Kazakhstan and Senegal?
- 5 years are reported by both, from 2018 to 2023.
- How do Kazakhstan and Senegal rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Kazakhstan ranks 13th and Senegal ranks 12th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.